Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:PRDS

Pardes Biosciences (PRDS) Stock Price, News & Analysis

Pardes Biosciences logo

About Pardes Biosciences Stock (NASDAQ:PRDS)

Key Stats

Today's Range
$2.16
$2.16
50-Day Range
$2.13
$2.16
52-Week Range
$0.75
$3.93
Volume
400 shs
Average Volume
359,530 shs
Market Capitalization
$133.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to treat and prevent viral diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California. As of August 31, 2023, Pardes Biosciences, Inc. operates as a subsidiary of MediPacific, Inc.

Receive PRDS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pardes Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PRDS Stock News Headlines

Pardes Biosciences Announces Closing of Tender Offer
Central Bank Abandons USD
You know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our exploding national debt, VOTE FOR GOLD!
See More Headlines

PRDS Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Pardes Biosciences investors own include Meta Platforms (META), Valneva (VALN), Arcturus Therapeutics (ARCT), Apellis Pharmaceuticals (APLS), Annexon (ANNX), ANI Pharmaceuticals (ANIP) and AnaptysBio (ANAB).

Company Calendar

Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:PRDS
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-96,630,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.51 per share

Miscellaneous

Free Float
36,711,000
Market Cap
$133.95 million
Optionable
Not Optionable
Beta
0.42
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:PRDS) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners